Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: A preliminary report

Journal of Clinical Psychiatry

Volumn 68, Issue 12, 2007, Pages 1954-1962

  Joffe, Hadine ^a   Petrillo, Laura F ^a   Viguera, Adele C ^a   Gottshcall, Hannah ^a   Soares, Claudio N ^a   Hall, Janet E ^a   Cohen, Lee S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESCITALOPRAM; ETHINYLESTRADIOL; FLUOXETINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTROGEN BLOOD LEVEL; FEMALE; HEADACHE; HORMONE URINE LEVEL; HUMAN; LUTEAL PHASE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 38049053425     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n1218     Document Type: Article

References (30)

1. Kornstein SG, Harvey AT, Rush AJ, et al. Self-reported premenstrual exacerbation of depressive symptoms in patients seeking treatment for major depression. Psychol Med 2005;35:683-692
2. Yonkers KA, White K. Premenstrual exacerbation of depression: one process or two? J Clin Psychiatry 1992;53:289-292
3. Rubinow DR, Hoban MC, Grover GN, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol 1988;158: 5-11
4. Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998;338:209-216
5. Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003;28(suppl 3): 39-53
6. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1991;72: 252A-252F
7. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501
8. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992; 36:257-266
9. Sulak PJ. Ovulation suppression of premenstrual symptoms using oral contraceptives. Am J Manag Care 2005;11(suppl 16):S492-S497
10. Coffee AL, Kuehl TJ, Willis S, et al. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006;195:1311-1319
11. Steiner M, Pearlstein T, Cohen LS, et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt) 2006;15:57-69
12. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press; 1996
13. Kearns NP, Cruickshank CA, McGuigan KJ, et al. A comparison of depression rating scales. Br J Psychiatry 1982;141:45-49
14. Endicott J, Harrison W. Daily Rating of Severity of Problems Form. Department of Research Assessment and Training. New York, NY: New York State Psychiatric Institute; 1990
15. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997;278:983-988
16. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571
17. Frisch MB, Cornell J, Villaneuva M. Clinical validation of the Quality of Life Inventory: a measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess 1992;4:92-101
18. Frisch MB. Manual and Treatment Guide for the Quality of Life Inventory. Minneapolis, Minn: National Computer Systems; 1994
19. Munro CJ, Stabenfeldt GH, Cragun JR, et al. Relationship of serum estradiol and progesterone concentrations to the excretion profiles of their major urinary metabolites as measured by enzyme immunoassay and radioimmunoassay. Clin Chem 1991;37:838-844
20. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996;54:71-77
21. Glick R, Harrison W, Endicott J, et al. Treatment of premenstrual dysphoric symptoms in depressed women. J Am Med Womens Assoc 1991; 46:182-185
22. Miller MN, Miller BE, Chinouth R, et al. Increased premenstrual dosing of nefazodone relieves premenstrual magnification of depression. Depress Anxiety 2002;15:48-51
23. Hendrick V, Altshuler LL, Burt VK. Course of psychiatric disorders across the menstrual cycle. Harv Rev Psychiatry 1996;4:200-207
24. Joffe H, Cohen LS. Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Biol Psychiatry 1998;44:798-811
25. Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-421
26. Willis SA, Kuehl TJ, Spiekerman AM, et al. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006;74:100-103
27. Blode H, Wuttke W, Loock W, et al. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contracept Reprod Health Care 2000;5:256-264
28. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38
29. Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 2003;189:1523-1530
30. Sanders SA, Graham CA, Bass JL, et al. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 2001;64:51-58